KTTA
Q4 2026 EPS Estimate
$-0.21
Nov 12, 2026 · Reports after close
Revenue Estimate
$200,000

Analyst Sentiment

Wall St. Consensus
Buy
2 analysts·Low coverage
75
Score
2 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$3.00
+500.8%
Consensus
$3.00
+500.8%
Bull
$3.00
+500.8%
12-Month Target Range2 analysts
$3.00$3.00$3.00
Current $0.50Consensus
Current Price
$0.50
Upside to Consensus
$2.50

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-5M$-7M$-9M
Low$-5M$-7M$-9M
High$-5M$-7M$-9M
EPS Avg$-0.76$-1.01$-1.30
Low$-0.76$-1.01$-1.30
High$-0.76$-1.01$-1.30
Analysts (Rev / EPS) / 1 / 1 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028
Revenue Avg$200,000$200,000$300,000
Low$200,000$200,000$300,000
High$200,000$200,000$300,000
EBITDA Avg$120,000$120,000$180,000
Low$120,000$120,000$180,000
High$120,000$120,000$180,000
EBIT Avg$120,000$120,000$180,000
Low$120,000$120,000$180,000
High$120,000$120,000$180,000
Net Income Avg$-7M$-8M$-109M$-109M$-109M$-116M$-122M
Low$-7M$-8M$-109M$-109M$-109M$-116M$-122M
High$-7M$-8M$-109M$-109M$-109M$-116M$-122M
EPS Avg$-0.21$-0.24$-3.40$-3.40$-3.40$-3.60$-3.80
Low$-0.21$-0.24$-3.40$-3.40$-3.40$-3.60$-3.80
High$-0.21$-0.24$-3.40$-3.40$-3.40$-3.60$-3.80
Analysts (Rev / EPS)1 / 11 / 11 / 1 / 1 / 1 / 1 / 1

Earnings Surprises

Recent Analyst Actions

Dec 8, 2025H.C. Wainwright
Pasithea Therapeutics initiated with a Buy at H.C. Wainwright
Target:$3.00
+165.5%from $1.13
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.